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Abstract
Background: Leukocyte telomere length (LTL) and mitochondrial genome (mtDNA) copy number and deletions
have been proposed as risk markers for various cancer types, including breast cancer (BC).
Methods: To gain a more comprehensive picture on how these markers can modulate BC risk, alone or in conjunction,
we performed simultaneous measurements of LTL and mtDNA copy number in up to 570 BC cases and 538 controls
from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. As a first step, we measured LTL
and mtDNA copy number in 96 individuals for which a blood sample had been collected twice with an interval of 15
years.
Results: According to the intraclass correlation (ICC), we found very good stability over the time period for both
measurements, with ICCs of 0.63 for LTL and 0.60 for mtDNA copy number. In the analysis of the entire study sample,
we observed that longer LTL was strongly associated with increased risk of BC (OR 2.71, 95% CI 1.58–4.65, p = 3.07 ×
10− 4 for highest vs. lowest quartile; OR 3.20, 95% CI 1.57–6.55, p = 1.41 × 10− 3 as a continuous variable). We did not
find any association between mtDNA copy number and BC risk; however, when considering only the functional copies,
we observed an increased risk of developing estrogen receptor-positive BC (OR 2.47, 95% CI 1.05–5.80, p = 0.04 for
highest vs. lowest quartile).
Conclusions: We observed a very good correlation between the markers over a period of 15 years. We confirm a role
of LTL in BC carcinogenesis and suggest an effect of mtDNA copy number on BC risk.
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Background
Mitochondria are responsible for essential functions in
the eukaryotic cell, such as energy metabolism, calcium
homeostasis, and apoptosis [1, 2]. Mitochondria are also
responsible for the generation of ROS, which is a by-
product of energy metabolism. They possess their own
genome (mitochondrial DNA [mtDNA]), and in each
eukaryotic cell, there can be hundreds or even thousands
of copies of their genomes [3]. mtDNA copy number re-
flects the number of mitochondria within each cell, and
this number is maintained within a constant range in
order to sustain the energetic needs of the cell [4]. Al-
though mtDNA copy number differs by cell type, it has
been observed that there is a good correlation between
the number of copies of mtDNA across different cell
types within the same individual [5]. Thus, measuring
mtDNA copy number in blood has been proposed as a
reliable and noninvasive method for estimating the aver-
age number of mitochondria in [5].
Over the last decade or so, several reports have sug-
gested that mtDNA content measured in blood may be a
risk factor for various diseases, including metabolic dis-
eases, diabetes, obesity, neurodegenerative diseases, and
cancer [5–13]. The majority of these studies suggest that
high mtDNA copy numbers are associated with increased
disease risk. One possible explanation for the association
of mtDNA copy number with chronic disease risk is oxi-
dative stress. The mitochondrial genome is particularly
prone to DNA damage and mutations caused by oxidative
stress, and mtDNA mutations are associated with in-
creased mtDNA copy number as a possible compensatory
mechanism to cope with mitochondrial dysfunction.
The study of mtDNA copy number variation in breast
cancer (BC) is of particular interest, given the role of
oxidative stress in the disease’s etiology [14–17]. Only
four studies have investigated the role of mtDNA copy
number in BC, and these suggested an association be-
tween high copy number and increased risk of develop-
ing the disease [5, 9, 13, 18]. All of these studies were
focused entirely or predominantly on estrogen receptor
(ER)-positive BC.
mtDNA deletions are a heterogeneous assortment of
mtDNA mutations in terms of length and position and
represent the major contributor to mitochondrial dys-
function [19]. Along the mtDNA circle, there are hot-
spot positions for deletions, and 90% of these include
the loss of the nicotinamide adenine dinucleotide de-
hydrogenase 4 (ND4) sequence [20]. The most frequent
deletion is the “common” deletion of 4977 bp, including
the ND4 sequence, which causes primary mitochondrial
diseases but has also been associated with age-related
disease susceptibility, such as cancer, muscle atrophy,
and neurodegeneration [21, 22]. Moreover, in a recent
study, Nie and colleagues reported that the common
deletion in the mitochondrial genome could increase the
risk of developing BC [23].
Besides oxidative stress, mitochondrial dysfunction
(measured as decreased mitochondrial mass and energy
production) recently has been associated with telomere
attrition and shortening, and mtDNA copy number has
been associated with leukocyte telomere length (LTL)
[24]. A possible mechanistic link between telomere
length and mitochondrial function has been proposed
through the peroxisome proliferator-activated receptor-γ
pathway [25]. To date, a number of studies have exam-
ined LTL in surrogate tissues in relation to cancer risks.
However, the results have been inconsistent, showing
positive, inverse, or null associations between telomere
length and cancer risk, with the majority reporting that
shorter telomere length increases the risk (reviewed in
[26–29]). In relation to BC risk, studies have shown con-
flicting results [26, 29]; however, none of these studies
were focused specifically on ER− BC risk.
To date, LTL and mtDNA copy number and deletion
levels have been examined mostly as independent con-
tributors to cancer risk. Recent studies have indicated
that LTL and mtDNA copy number are positively corre-
lated in healthy individuals, in pregnant women, and in
patients with psychological disorders [24, 30, 31]. More-
over, very recently, it has been demonstrated that LTL
and mtDNA copy number are correlated in intestinal
gastric cancer [32]. Hence, there is emerging evidence
that the markers are linked biologically and that their
joint measurement may increase their predictive value
for cancer risk. Therefore, to gain a more comprehensive
picture of how the markers mentioned above can modu-
late BC risk, alone or in conjunction, we measured
mtDNA copy number, LTL, and mtDNA deletions in the
context of the European Prospective Investigation into
Cancer and Nutrition (EPIC) cohort. In addition, given
the fact that ER− BC has been greatly understudied for
these markers, we collected a fairly large number of
them (n = 251).
Methods
Study population: the EPIC cohort
The EPIC cohort has been described in full detail else-
where [33]. Briefly, EPIC consists of about 520,000
healthy volunteers, aged 35–69 years, who were re-
cruited between 1992 and 2005 in 10 European coun-
tries. All EPIC study subjects provided anthropometric
measurements (height, weight, and waist and hip cir-
cumferences) and extensive standardized questionnaire
information about medical history, diet, physical activity,
smoking, and other lifestyle factors. The women also an-
swered questions about menstrual and reproductive his-
tory, hysterectomy, ovariectomy, and use of exogenous
hormones for contraception or treatment of menopausal
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symptoms. About 260,000 women and 140,000 men pro-
vided a blood sample, which was split into aliquots of
plasma, serum, buffy coat, and erythrocytes and stored
frozen for later laboratory analyses.
Cases of cancer occurring after recruitment into the
cohort and blood donation are identified through local
and national cancer registries or by a combination of
contacts with national health insurance and/or active
follow-up through the study subjects or their next of
kin. Cancer incidence data are classified according to the
International Classification of Diseases, Tenth Revision
(ICD-10), system. Incident cases of BC were identified as
first occurrence of primary invasive tumors, ICD-10
code C50, occurring among women who had no previ-
ous diagnosis of cancer. Since 2001, an expanding series
of nested case-control studies have been conducted on
hormonal, metabolic, and other blood-based risk factors
for BC [34–37], as well as on genetic determinants [14,
38–45]. For these latter studies, the cases and controls
were not individually matched; however, care was taken
to select the controls randomly from the cohort to avoid
selection bias. Because there were insufficient amounts
of biological material (extracted buffy coat DNA) for
some of the selected controls, we retained slightly un-
even numbers of invasive BC cases. We had measure-
ments on telomere length for 570 controls and 533
cases, measurements on mtDNA copy number on 548
controls and 522 cases, and measurements on mtDNA
deletions on 539 controls and 519 cases. This study was
approved by the ethical review board of the International
Agency for Research on Cancer.
Sample preparation and DNA extraction
All blood specimens were kept frozen in liquid nitrogen
at the International Agency for Research on Cancer.
DNA was extracted from blood samples on an Autopure
instrument (Qiagen, Hilden, Germany) with Puregene
chemistry (Qiagen). All of the samples were extracted
using the same method and in batches of 96 to avoid
any possible bias due to sample handling. The order of
DNA from cases and controls was randomized on PCR
plates, and each batch cases and controls was chosen to
be from the same study center.
LTL and mtDNA copy number/deletion measurement
LTL was measured by real-time qPCR as the number of
copies of telomeric repeats compared with a single copy
gene (RPLP0) used as a quantitative control. For each
sample plate, a standard curve was prepared by using a
serially diluted reference DNA (range 0.468–30 ng/μl).
The relative length of telomeres (T) compared with the
control gene (S) was calculated as the ratio T/S. All the
samples were analyzed in triplicate. mtDNA copy num-
ber and deletions were also analyzed by qPCR. The
mtDNA/nuclear DNA content was assessed using specific
primers designed for the mitochondrial ND1 gene and the
nuclear β-actin gene. The ratio between these two genes
(ND1/β-actin) identifies the relative mtDNA copy number
[46]. To quantify mtDNA deletions, primers for the mito-
chondrial gene ND4, located in the major arch of the
mtDNA where deletion frequently occurs, were used in
combination with those of the mitochondrial gene ND1,
which is rarely deleted. The mtDNA deletion level is re-
ported as the ratio between ND4 and ND1 [47] and thus
represented by the quantification of the nondeleted frac-
tion of mtDNA (ND4) vs. the total amount of mtDNA
(ND1). As for the LTL measurement, for the analysis of
mtDNA, a standard curve was also used in each plate.
Four samples were included in all plates for all the assays
for quality control.
Longitudinal assessment of LTL and mtDNA copy number
To assess the reliability of the measure of mtDNA con-
tent and LTL over time, we compared the measurements
of these two markers obtained from samples collected
15 years apart from a set of 96 samples of healthy indi-
viduals randomly selected from among the EPIC Heidel-
berg cohort. We calculated intraclass correlations (ICCs)
by dividing the between-person variance by the total
variance (sum of between- and within-person variances)
[48]. ICCs ≥ 0.75 are considered an indicator of excellent
reliability; ICCs between 0.51 and 0.74, good reliability;
ICCs between 0.40 and 0.50, fair reliability; and ICCs ≤
0.40, poor reliability. This threshold has been selected
according to a similar study done on 100 EPIC subjects
in which researchers evaluated the reliability of serum
metabolite measurements [49].
Statistical analysis
Quantitative measurements of LTL and mtDNA copy
number were log-transformed to obtain variables with
an approximately normal distribution. The relationships
of age, smoking, and body mass index (BMI) on the bio-
markers (LTL and mtDNA copy number/deletion) were
examined by linear regression, adjusting for plate num-
ber, center, and case-control status. Correlation between
the biomarkers (LTL vs. mtDNA copy number, LTL vs.
mtDNA, mtDNA copy number vs. deletion) was exam-
ined by calculating Pearson’s correlation coefficients and
corresponding p values.
To examine the relationships of LTL and mtDNA copy
number in relation to BC risk, we used unconditional lo-
gistic regression to obtain ORs and 95% CIs adjusted for
age, center, smoking status, BMI, and plate. We also per-
formed stratified analyses by ER status. LTL and mtDNA
copy number were analyzed as continuous variables, and
as ordinal variables using quartile cutpoints for the vari-
able distributions among the controls. To investigate the
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aggregated effects of mtDNA copy number together with
LTL for each individual, the quartiles of the log-
transformed values of the markers were added together,
creating a score with values ranging from 2 to 8. The
score was investigated as a continuous variable account-
ing for age, center, and plate. Finally, we investigated the
ratio between mtDNA deletion level and mtDNA copy
number in relation to BC risk. This measure represents
the proportion of intact molecules relative to the total
number of mtDNA (calculated as ND1/nuclear DNA
content) molecules per subject.
Considering the number of statistical tests carried out
in the present set of analyses, the threshold for statistical
significance had to be corrected to avoid false-positive
findings. Although it is not reasonable to assume that
the three markers are independent, we preferred a con-
servative approach and thus considered the p value
threshold of (0.05/3) < 0.017.
Results
In the first step, we measured LTL and mtDNA copy
number in 96 individuals belonging to the EPIC Heidel-
berg cohort, from whom a blood sample was collected at
2 time points approximately 15 years apart. Both mea-
surements showed good stability over this 14- to 15-year
period, with ICCs of 0.63 for LTL and 0.60 for mtDNA.
Given the good reliability of the estimates, we then mea-
sured LTL and mtDNA copy number in 570 invasive BC
cases and 538 control subjects recruited in the context
of the prospective EPIC study. Four samples were in-
cluded in all plates and analyzed in all assays for quality
control. The highest observed coefficient of variation
(CV) among these samples and across assays was 5.52%,
and the average CV over all samples and all assays was
3.06%.
We also calculated CVs on the seven dilutions of the
sample used as standard across genotyping plates and
assays. The highest observed CV was 3.46%, and the
average CV over all samples and all assays was 2.02%.
Regarding the distribution of LTL and mtDNA mea-
sures across different strata of risk covariates (Table 1),
age was, as expected, inversely related to LTL (p = 1.66
× 10− 11) but was not associated with the mtDNA
genome variables. Smoking did not show any association
with the three markers measured, whereas BMI was
significantly associated with mtDNA copy number,
though with a modest effect size (correlation coefficient
0.009, p = 0.005). Similarly to a previous study [24], we
also observed a modest but statistically significant,
correlation between telomere length and mtDNA copy
number (correlation coefficient 0.16, p = 7.3 × 10− 4),
whereas there was no correlation between the other two
markers (Additional file 1: Table S1).
We observed that longer LTL was strongly associated
with increased risk of BC when analyzing LTL as a cat-
egorical variable (OR 2.71, 95% CI 1.58–4.65, p = 3.07 ×
10− 4 for highest vs. lowest quartile) and also as a
continuous variable (OR 3.20, 95% CI 1.57–6.55, p = 1.
41 × 10− 3). When we stratified the analysis by ER status
of cancer, we observed that longer telomeres were
associated with increased risk of both ER− BC (OR 2.12,
95% CI 1.04–4.31, p = 3.84 × 10− 2 for highest vs. lowest
quartile) and ER+ BC (OR 2.55, 95% CI 1.10–5.86, p =
2.82 × 10− 2 for highest vs. lowest quartile). All results
from the fully adjusted analyses on LTL and BC risk are
shown in Table 2. (Minimally adjusted models are
shown in Additional file 2: Table S2.)
For mtDNA copy numbers, we did not observe any
differential association between cases and controls when
considering quartiles. Also, the stratified analysis (ER
+/ER−) did not show any statistically significant differ-
ences between cases and controls (Table 3). The results
of the minimally adjusted models are shown in
Additional file 3: Table S3. However, we included in the
analysis the ratio between mtDNA deletion level and
mtDNA copy (ND4/ND1 divided by ND1/nuclear gen-
ome). When comparing this measure across cases and
controls, we observed an increase in risk with increased
number of copies. This difference was statistically sig-
nificant only for ER+ BC. When analyzed as a categor-
ical variable, unconditional logistic regression models
showed a significant association of ER+ BC with mtDNA
integrity (OR 2.47, 95% CI 1.05–5.80, for highest vs. low-
est quartile) (Table 4). The results of the minimally ad-
justed models are shown in Additional file 4: Table S4.
Finally when analyzing the score (computing the aggre-
gate effect of mtDNA copy number and LTL) as a con-
tinuous variable, we observed an increased risk for
Table 1 Association between selected markers and age, smoking, and body mass index
Marker Agea Smokingb BMIb
Effect (SE) p value Effect (SE) p value Effect (SE) p value
Telomere length − 0.004 (0.001) 1.6 × 10− 5 − 0.002 (0.01) 0.84 − 0.0009 (0.002) 0.90
mtDNA copy number 0.002 (0.002) 0.33 0.04 (0.02) 0.04 0.009 (0.0032) 0.005
mtDNA deletions 0.0004 (0.0008) 0.65 − 0.01 (0.009) 0.10 0.001 (0.0014) 0.32
BMI Body mass index, mtDNA Mitochondrial DNA
aThe analyses were adjusted for plate and case-control status
bThe analyses were adjusted for age, plate, and case-control status
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individuals with a high score compared with individuals
with a low score (OR 1.20, 95% CI 1.05–1.37, p = 0.009).
This trend was present in all the strata but was signifi-
cant only in the analysis considering ER+ and ER− to-
gether (Table 5).
Discussion
Given their central role in several essential functions of
the eukaryotic cell, mitochondria—and in particular mito-
chondrial mutations—have been extensively investigated
in relation to human cancer. A growing number of som-
atic mitochondrial mutations have been implicated in sev-
eral cancer types, including BC [50, 51]. In addition, the
common germline variability in the mitochondrial gen-
ome (deletions, mitochondrial single-nucleotide polymor-
phisms, and resulting mitochondrial haplogroups) has
been associated with risk of various cancers, such as of
the lung, pancreas, and breast [50, 52–54]. Several studies
have suggested that, to counterbalance mitochondrial dys-
function caused by genetic mutations, the eukaryotic cell
Table 2 Associations between leukocyte telomere length and breast cancer risk
Stratum Relative LTLa Controls Cases OR 95% CI p value
Overall Quartile 1 (0.36–0.63) 134 81 Reference – –
Quartile 2 (0.63–0.75) 126 102 1.60 (1.04–2.46) 3.17E-02
Quartile 3 (0.75–0.93) 134 172 2.28 (1.46–3.57) 2.89E-04
Quartile 4 (0.93–1.94) 139 215 2.71 (1.58–4.65) 3.07E-04
Continuous variable 533 570 3.20 (1.57–6.55) 1.41E-03
ER+ Quartile 1 (0.36–0.63) 134 41 Reference – –
Quartile 2 (0.63–0.75) 126 45 1.59 (0.88–2.89) 1.25E-01
Quartile 3 (0.75–0.93) 134 77 2.97 (1.54–5.72) 1.11E-03
Quartile 4 (0.93–1.94) 139 86 2.55 (1.10–5.86) 2.82E-02
continuous variable 533 249 3.33 (1.17–9.46) 2.38E-02
ER− Quartile 1 (0.36–0.63) 134 28 Reference – –
Quartile 2 (0.63–0.75) 126 40 1.25 (0.65–2.44) 5.05E-01
Quartile 3 (0.75–0.93) 134 79 1.67 (0.88–3.16) 1.19E-01
Quartile 4 (0.93–1.94) 139 104 2.12 (1.04–4.31) 3.84E-02
Continuous variable 533 251 2.33 (0.88–6.15) 8.92E-02
ER Estrogen receptor, LTL Leukocyte telomere length
aAnalyses are adjusted for age, body mass index, smoking, center of origin, and plate
Table 3 Associations between mitochondrial DNA copy number and breast cancer risk
Stratum mtDNA copy numbera Controls Cases OR 95% CI p value
Overall Quartile 1 (0.11–0.21) 132 117 Reference – –
Quartile 2 (0.21–0.29) 132 148 1.48 (1.00–2.20) 5.24E-02
Quartile 3 (0.29–0.47) 125 122 1.30 (0.81–2.11) 2.77E-01
Quartile 4 (0.47–1.52) 133 161 0.93 (0.53–1.66) 8.18E-01
Continuous variable 522 548 0.97 (0.66–1.42) 8.75E-01
ER+ Quartile 1 (0.11–0.21) 132 68 Reference – –
Quartile 2 (0.21–0.29) 132 94 1.43 (0.85–2.39) 1.77E-01
Quartile 3 (0.29–0.47) 125 65 1.23 (0.65–2.32) 5.22E-01
Quartile 4 (0.47–1.52) 133 18 0.46 (0.18–1.13) 8.95E-02
Continuous variable 522 245 0.67 (0.36–1.25) 2.11E-01
ER− Quartile 1 (0.11–0.21) 132 41 Reference – –
Quartile 2 (0.21–0.29) 132 42 1.33 (0.74–2.38) 3.43E-01
Quartile 3 (0.29–0.47) 125 35 0.90 (0.43–1.91) 7.91E-01
Quartile 4 (0.47–1.52) 133 140 0.94 (0.44–2.02) 8.81E-01
Continuous variable 522 258 1.04 (0.64–1.69) 8.79E-01
ER Estrogen receptor, mtDNA Mitochondrial DNA
aAnalyses are adjusted for age, body mass index, smoking, center of origin, and plate
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increases their number. Mitochondrial copy number has
been proposed as a risk marker for various cancer types
[5–7, 9, 10, 12, 13]. In a small exploratory study on BC,
Shen and colleagues reported an association between high
mtDNA copy number and increased risk of the disease
[5]. This association was subsequently replicated in two
independent studies focused primarily on ER+ BC [9, 13]
and again by Shen and colleagues [18].
Telomeres are specialized structures that adorn the
telomeric end of the eukaryotic chromosomes and are
essential for the correct segregation of chromosomes to
daughter cells [55] as well as for the control of chromo-
somal stability and regulation of cell growth [56–58]. In
the past several years, there has been an overwhelming
number of studies aimed at understanding the role of
telomere length, measured in blood, in relation to can-
cer risk and progression. The results, however, are often
inconclusive, with some articles reporting an associ-
ation between increased risk of developing various can-
cer types and longer telomeres and others reporting the
opposite, no association at all, or even a nonlinear
dose-response association with increased risks only at
the two extremes of the LTL distribution (very short
and very long LTL) [26–29].
LTL and mtDNA copy number have largely been ex-
amined as independent contributors to cancer risk; yet,
there is emerging evidence that the markers are linked
biologically or at least that measuring them together in-
creases the efficiency of the estimation of their effect.
For example, Bao and colleagues [59] analyzed LTL and
mtDNA as progression markers for hepatocellular car-
cinoma and observed that the combination of the two
was a better indicator than each of the two separately.
Moreover, it has been demonstrated that LTL and
mtDNA copy number are correlated in intestinal gastric
cancer [32]. Recently, an association between mitochon-
drial dysfunction and telomere length attrition has been
suggested, and a correlation between LTL and mtDNA
has been observed by several authors [24, 31, 60]. Both
telomere length and mitochondrial function have been
proposed as markers of aging (although the evidence is
much stronger for telomeres). Mice null for either the
telomerase reverse transcriptase (Tert) or telomerase
RNA component (Terc) gene had marked repression of
peroxisome proliferator-activated receptor-γ, coactivator
1 alpha and beta, and the downstream network. Consist-
ent with peroxisome proliferator-activated receptors as
master regulators of mitochondrial physiology and me-
tabolism, telomere dysfunction, including shortening,
was associated with impaired mitochondrial biogenesis
and function, decreased gluconeogenesis, cardiomyop-
athy, and increased ROS [25].
Given the mounting evidence of possible combined as-
sociations of cancer risk with LTL and mtDNA, we
Table 4 Associations between mitochondrial DNA integrity (ND4/ND1 divided by ND1/nuclear genome) and breast cancer risk
Stratum mtDNA integritya Controls Cases OR 95% CI p value
Overall Quartile 1 (0.34–0.90) 129 152 Reference
Quartile 2 (0.90–1.00) 126 102 1.06 (0.68–1.66) 0.79
Quartile 3 (1.00–1.11) 133 142 1.56 (0.95–2.56) 0.08
Quartile 4 (1.11–2.59) 130 142 1.20 (0.69–2.08) 0.52
Continuous variable 519 539 1.07 (0.75–1.52) 0.73
ER+ Quartile 1 (0.34–0.90) 129 20 Reference – –
Quartile 2 (0.90–1.00) 126 50 1.61 (0.78–3.35) 0.20
Quartile 3 (1.00–1.11) 133 79 2.59 (1.19–5.66) 0.02
Quartile 4 (1.11–2.59) 130 89 2.47 (1.05–5.80) 0.04
Continuous variable 519 238 1.54 (0.87–2.72) 0.14
ER− Quartile 1 (0.34–0.90) 129 128 Reference – –
Quartile 2 (0.90–1.00) 126 40 0.98 (0.55–1.74) 0.94
Quartile 3 (1.00–1.11) 133 47 1.22 (0.62–2.39) 0.56
Quartile 4 (1.11–2.59) 130 41 0.96 (0.46–2.00) 0.92
Continuous variable 519 256 0.99 (0.63–1.54) 0.95
ER Estrogen receptor, mtDNA Mitochondrial DNA
aAnalyses are adjusted for age, body mass index, smoking, center of origin, and plate
Table 5 Associations between a biomarker score created from
leukocyte telomere length and mitochondrial DNA copy number
and breast cancer risk
Stratum Controls Cases OR 95% CI p value
Overall 522 548 1.20 (1.05–1.37) 0.009
ER+ 522 245 1.18 (0.96–1.45) 0.11
ER− 522 258 1.16 (0.98–1.38) 0.09
ER Estrogen receptor
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sought to investigate, for the first time in the same
study, the two markers with the addition of mtDNA de-
letion in order to gain a more comprehensive picture of
their involvement in BC risk. Given the large number of
caveats linked to these measurements as a first prelimin-
ary step, we wanted to determine how stable the mea-
surements were. To do so, we isolated DNA from blood
samples taken 15 years apart from 96 individuals. We
observed a very good stability over time for both LTL
(ICC 0.63) and mtDNA copy number (ICC 0.60). These
values probably underestimate the real correlations be-
cause the starting material was not exactly the same:
The DNA collected at baseline was isolated from buffy
coat, whereas for the samples collected after 15 years,
the extraction was done starting from whole blood.
In the cross-sectional analysis, our results suggest a
clear association between longer telomeres and in-
creased risk of BC independent of ER status. The associ-
ation between longer telomeres and increased BC risk is
biologically plausible because longer LTL may be a
marker of an actively reproducing cell and therefore a
cell that keeps dividing and that is exposed to an in-
creased risk of acquiring tumor-causing mutations. The
association between longer or shorter LTL and cancer
risk could also be tumor-specific and may reflect the
complex interaction between the genetic determination
of telomere length and the environmental risk factors
specific for each cancer type.
The analyses of our data did not show any strong asso-
ciation between mtDNA, when analyzed alone, and BC
risk, contrary to what has been observed by others [5, 9,
13, 18]. Authors of two recent meta-analyses investi-
gated the role of mtDNA copy number in a large num-
ber of studies across different tumors and highlighted
the great heterogeneity of the mtDNA effect in different
cancer types and a null overall effect [61, 62]. Interest-
ingly, also the four studies in which researchers reported
the association with BC showed a high degree of hetero-
geneity, possibly explaining the difference between those
studies and our findings. However, when normalizing for
mitochondrial deletions and using the mitochondrial in-
tegrity variable, we did observe an increase in risk with a
higher number of functional copies. This association is
biologically plausible because an increase in mtDNA
copy number may reflect increased oxidative stress that
in turn may increase damage levels, fuel inflammation
[63], and finally increase the risk of developing BC. One
of the novelties of our report is the introduction of a
measure of mitochondrial genome integrity and the pos-
sibility of observing the effect of functional mitochon-
drial copy number in cancer risk instead of just
measuring the effect mtDNA copy number regardless of
their status. Given that when considering mtDNA copy
number alone we did not see any association with BC
risk, we hypothesize that this “correction,” at least in
part, could explain the differences and heterogeneity ob-
served across previous reports. Analyzing the score of
mtDNA and LTL, we observed an association with in-
creased risk for the individuals with a high score; how-
ever, this probably reflects the association between LTL
and BC risk.
This study has several clear strengths, one being its
prospective design, which, to a certain extent, may re-
duce the possibility of reverse causation, which is a crit-
ical point when looking for the relationship between
LTL, mtDNA, and cancer risk. A second strength is the
possibility of avoiding possible confounders by adjusting
for all known potential confounding factors on which in-
formation was available, such as smoking, BMI, and al-
cohol consumption. In addition, our data suggest that
our calculations of the LTL and mtDNA ratios are un-
likely to be heavily affected by sample handling or tech-
nical errors, given that even at 15 years apart the
measurements remained comparable. A possible limita-
tion of the present study is the relatively small sample
size, which is partially counterbalanced, however, by the
rather large number of ER− BC cases.
Conclusions
We observed a very good correlation between the markers
across a period of 15 years, highlighting how sample hand-
ling is crucial for this kind of analysis. Moreover, we also
observed a strong and consistent association between lon-
ger telomere length and increased BC risk, and additionally,
we found a novel association between the mitochondrial
genome stability and ER+ BC risk.
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